Print（PDF/166KB） Apr. 28, 2023 Finances

Notice Concerning Finance Income

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) announced today that it will record finance income for the year ended March 31, 2023 as follows.

1. Details of Finance Income

The Company will record a foreign exchange gain of 7,867 million yen under finance income for the three months ended March 31, 2023 due to recent fluctuations in foreign exchange rates. This was mainly due to the valuation of assets denominated in foreign currencies.
In addition, foreign exchange gains for the year ended March 31, 2023 will total 26,308 million yen, because financial income (foreign exchange gain) of 18,441 million yen was recorded in the nine months ended December 31, 2022.

2. Future Outlook

Regarding the impact of the above finance income on the results of the Company operations, please refer to the “Sumitomo Pharma Announces Revisions to Its Financial Forecasts” announced today.